Modality
Small Molecule
MOA
IL-13i
Target
LAG-3
Pathway
Hedgehog
CF
Development Pipeline
Preclinical
~Nov 2019
→ ~Feb 2021
Phase 1
~May 2021
→ ~Aug 2022
Phase 2
~Nov 2022
→ ~Feb 2024
Phase 3
May 2024
→ Sep 2028
Phase 3Current
NCT06947879
1,339 pts·CF
2024-05→2028-09·Terminated
1,339 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-262.5y awayPh3 Readout· CF
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Termina…
Catalysts
Ph3 Readout
2028-09-26 · 2.5y away
CF
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06947879 | Phase 3 | CF | Terminated | 1339 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| ALN-6288 | Alnylam | Approved | LAG-3 |